Business Wire

MA-NOVOTECH

Share
Transforming the Future of Medicine with RNA-Based Therapies

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, RNA Therapies — Global Clinical Trial Landscape (2024).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240825825969/en/

This report details how RNA-based therapies have transitioned from a novel concept to an exciting frontier in modern medicine, demonstrating enormous potential for the treatment of diseases through highly-targeted mechanisms. It also provides a comprehensive overview of the current landscape, advancements, and future prospects of RNA therapeutics, focusing on their transformative impact on healthcare, and is available free of charge.

RNA therapies are at the forefront of medical advancements, poised to redefine the way we approach the treatment of some of the most challenging diseases known to humanity. RNA-based therapies offer a new frontier of therapeutic options with their versatility, effectiveness, and incredible adaptability.

The success of mRNA vaccines in the fight against COVID-19 was a clear example of how RNA therapies represented a practical option for large-scale development, as well as targeted medicine. The potential isn’t limited to vaccinations, but can also be used to combat infectious diseases, various types of cancers, and potentially offer an effective and economical way to address rare genetic disorders. The ability to target any gene in the human genome offers a breadth of potential far beyond what traditional therapies can currently achieve.

A factor that is of particular interest to medical research in RNA therapies is the unparalleled programmability. These are treatments that can be tailored with incredible precision, designed to target specific genetic markers and be modified rapidly to adapt to emerging challenges. The advancements in RNA delivery systems, such as lipid nanoparticles, are pushing the boundaries even further, ensuring that these therapies are not only effective but also safe and scalable.

The report touches on these major themes:

  • Versatility of RNA Therapies:
    • RNA-based therapies can target any gene, offering broad therapeutic potential beyond traditional drugs that focus solely on proteins.
    • They are “programmable drugs,” allowing for rapid and flexible production, akin to gene-modified cell therapies.
  • Success of mRNA Vaccines:
    • The COVID-19 pandemic showcased the power of mRNA technology, leading to its rapid development and global deployment.
    • The success of Pfizer and BioNTech's COVID-19 vaccine has set a precedent for further RNA-based vaccine developments targeting other infectious diseases, cancers, and metabolic disorders.
  • Clinical Trials and Global Landscape:
    • There has been significant growth in RNA therapy trials globally, with the Asia-Pacific region leading in trial growth rate.
    • The most common areas of application include infectious diseases, oncology, and rare genetic disorders.
  • Innovation in Delivery Methods:
    • Advancements in delivery technologies such as lipid nanoparticles (LNPs) have enhanced the stability and effectiveness of RNA therapies, reducing potential side effects.
  • Investment and Market Growth:
    • There has been a substantial increase in public and private funding for RNA research, particularly in the United States and China.
    • The market for RNA-based therapeutics is expected to grow significantly, driven by ongoing advancements and the successful application of these therapies in diverse areas.
  • Regulatory Landscape:
    • The FDA has approved over 20 RNA-based therapies, with many more in the pipeline, highlighting the evolving regulatory environment that is facilitating the rapid development of these treatments.
    • Many different entities are pursuing new RNA-based technologies, which has increased significantly since the rollout of the mRNA COVID-19 vaccine.

The report highlights how the field is poised for substantial growth, driven by significant advancements in technology, increased funding, and successful clinical outcomes. RNA therapies have the potential to play a significant role in advancing patient care and invites continued interest and investment in this rapidly evolving field.

For more information and to download the full report free of charge, please visit Novotech's website or contact our media relations team.

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-cro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240825825969/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success10.10.2024 11:30:00 CEST | Press release

Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/ Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire) Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sop

Thredd Reports Another Successful Quarter With Fintech Transaction Volumes up and New Issuer Signings10.10.2024 11:08:00 CEST | Press release

20% YOY organic transaction volume growth and new client signings in APAC and the U.S. 48% increase YOY in Buy Now Pay Later (BNPL) solutions across the UK, Europe, and APAC regions B2B virtual card payments up significantly with APAC clients leading the charge Thredd, a leading next-generation payments processor, today announced positive third-quarter results with 2024 on track to outperform all prior years, powered by transactions up 20%, key global client wins, programme expansions and growth in distinct payment segments and markets. According to the company, Thredd signed key new clients in the third quarter including digital banks and saw existing B2B programme expansion to the US. The company also announced the launch of virtual card programmes and a major card programme migration in APAC. The company said these wins and programme launches follow other partnership extensions earlier in the summer with segment leaders in Buy Now Pay Later (BNPL), B2B payments, disbursements, and s

Allianz Is the World’s #1 Insurance Brand, Ranking Among the Top 30 Global Brands for the First Time10.10.2024 11:03:00 CEST | Press release

Interbrand 2024 Best Global Brands ranking: Allianz jumps to 29th position and further maximises brand value to 23,5 billion USD.Strong employee value proposition: Allianz also climbed to 7th place in the Fortune 100 Best Companies to Work For® in Europe 2024 certification.The 2024 Olympic and Paralympic Games in Paris have been the biggest marketing asset to date for Allianz, uniting athletes from over 200 nations and billions of fans in peaceful competitions.Disaster relief efforts for flood events and sustainability commitments contribute to building trust in the Allianz brand. Allianz's steady rise to the top of the world's most powerful brands continued in 2024, driven by a strong employee value proposition, a commitment to building trust through sustainability and societal leadership as well as top-tier partnerships in sport. For the first time, Allianz has been named one of the 30 most valuable brands in the world, moving up two places to the 29th position in this year’s Best Gl

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research10.10.2024 09:01:00 CEST | Press release

The San Francisco-based company with an R&D facility in Bilbao has also unveiled its Platforma.bio Software Development Kit, transforming how biologists analyze genomic data to drive drug discovery and advance adjacent fields in medicine. This latest financing bolsters the company's efforts to transform computational biology on a global scale and empower researchers with innovative tools to accelerate discoveries and advancements in the field Led by Kfund with participation from Speedinvest, Acrobator Ventures, Ten13, Somersault Ventures, EGB Capital, and Courtyard Ventures Series A capital to be utilized for attracting top-tier talent and expanding into new markets, with a strategic emphasis on the United States MiLaboratories, a leader in computational biology innovation, is thrilled to announce the successful close of its Series A funding round, led by Madrid-based Kfund, with additional backing from Speedinvest and other prominent international investors. This funding milestone com

Delinea Recognized as a Leader in the KuppingerCole Leadership Compass™ for Privileged Access Management (PAM) 202410.10.2024 09:00:00 CEST | Press release

Delinea’s Continued Innovation and Comprehensive Approach to Identity Security Highlighted in Leading Analyst Report Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the KuppingerCole Leadership Compass for Privileged Access Management (PAM), 2024. This marks another significant milestone for Delinea as it continues to lead the industry in providing secure and scalable PAM solutions that empower organizations to safeguard their most critical identities and assets. “We are honored to be recognized as a Leader in the 2024 KuppingerCole Leadership Compass for PAM,” said Art Gilliland, CEO of Delinea. “This achievement reflects our commitment to developing innovative solutions for the growing complexity of identity security. With our broad product portfolio and cloud-first approach, Delinea has established itself as a market leader known for ease of use. As human and machine identities incr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye